AGIO vs. LEGN, CTLT, ITCI, CERE, ROIV, ASND, IONS, BPMC, SMMT, and JAZZ
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Legend Biotech (LEGN), Catalent (CTLT), Intra-Cellular Therapies (ITCI), Cerevel Therapeutics (CERE), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Summit Therapeutics (SMMT), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
Legend Biotech (NASDAQ:LEGN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.
Agios Pharmaceuticals received 410 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 67.96% of users gave Legend Biotech an outperform vote while only 67.13% of users gave Agios Pharmaceuticals an outperform vote.
Agios Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Legend Biotech has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
Legend Biotech currently has a consensus price target of $81.31, indicating a potential upside of 43.64%. Agios Pharmaceuticals has a consensus price target of $50.67, indicating a potential upside of 5.45%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Legend Biotech is more favorable than Agios Pharmaceuticals.
Legend Biotech has a net margin of -135.92% compared to Legend Biotech's net margin of -1,199.26%. Agios Pharmaceuticals' return on equity of -27.91% beat Legend Biotech's return on equity.
In the previous week, Legend Biotech had 4 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 13 mentions for Legend Biotech and 9 mentions for Agios Pharmaceuticals. Legend Biotech's average media sentiment score of 0.89 beat Agios Pharmaceuticals' score of 0.59 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.
Summary
Legend Biotech beats Agios Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
Free AGIO Stock Alerts